insulin detemir vs insulin glargine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
insulin detemir · Levemir
Rights held by Novo Nordisk; US product discontinued
NCT00283751 · Phase 3 · completed
The study randomized 583 participants to insulin detemir or insulin glargine, but it was open-label rather than blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Insulin Detemir + Lira 1.8 -0.51 Percentage point of total HbA1c (Standard Error 0.07) vs Lira 1.8 0.02 Percentage point of total HbA1c (Standard Error 0.07) (met)
Result source: NCT00856986
insulin glargine · Lantus
Marketed by Sanofi
NCT00069784 · Phase 3 · completed
The trial randomized 12,537 participants and used adjudicated clinical cardiovascular events, but treatment assignment was open-label rather than double-blinded. Neither primary cardiovascular endpoint was statistically significant in favor of insulin glargine, so the evidence supports a well-powered but inconclusive or negative finding rather than strong evidence of benefit.
Next expected readout: June 2027 · NCT07173712 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | insulin detemir | insulin glargine |
|---|---|---|
| HbA1c, change | -0.5% vs 0.0%vs Lira 1.8NCT008569866 other results
| -0.6% vs -0.8%vs Insulin IcodecNCT0634085418 other results
|
| Body weight, change (kg) | -0.2 vs -0.9vs Lira 1.8NCT008569868 other results
| 0.6 vs 2.0vs Insulin IcodecNCT063408547 other results
|
| HbA1c below 7% | —Not posted · NCT00283751 | 48.4% vs 45.9%vs LiraglutideNCT011173504 other results
|
| Fasting plasma glucose, change | -2.1 vs -0.4vs Lira 1.8NCT008569862 other results
| -3.6 vs -2.1vs LiraglutideNCT011173504 other results
|
| 3-point MACE (% with event) | —Not posted · NCT00283751 | —Not posted · NCT00044447 |
HbA1c, change
- insulin detemir
- -0.5% vs 0.0%vs Lira 1.8NCT00856986
6 other results
- -0.5% vs -0.1% NCT00856986
- -0.5% vs 0.0% NCT00856986
- -0.5% vs -0.7% NCT00909480
- -1.0% vs -1.1% NCT01165684
- -0.8% vs -1.1% NCT01165684
- -0.5% vs -1% NCT01165684
- insulin glargine
- -0.6% vs -0.8%vs Insulin IcodecNCT06340854
18 other results
- -1.0% vs -1% NCT05462756
- -1.0% vs -1% NCT05462756
- -1.7% vs -1.4% NCT00391027
- -2.0% vs -1.8% NCT00418522
- -1.7% vs -1.1% NCT00751114
- -1.3% vs -1.4% NCT00686712
- -1.9% vs -1.4% NCT00686712
- -1.3% vs -1.4% NCT02455076
- -1.1% vs -1.4% NCT02455076
- -1.9% vs -1.7% NCT00418522
- -1.9% vs -1.8% NCT01117350
- -0.4% vs -0.1% NCT00360698
- -1.7% vs -1.5% NCT00391027
- -1.6% vs -1.3% NCT00391027
- -1.3% vs -1.1% NCT00391027
- -0.8% vs -0.6% NCT00391027
- -0.4% vs -0.3% NCT00391027
- -2.5% vs -2.1% NCT00384085
Body weight, change (kg)
- insulin detemir
- -0.2 vs -0.9vs Lira 1.8NCT00856986
8 other results
- -0.8 vs -1.7 NCT00789191
- -0.1 vs -1.0 NCT00856986
- 1.9 vs 5.7 NCT00184600
- 3.6 vs 6.4 NCT00184600
- -0.5 vs 1 NCT00909480
- 0.3 vs 0.8 NCT00998335
- 13 vs 12.6 NCT01837680
- 1.2 vs 2.8 NCT00604396
- insulin glargine
- 0.6 vs 2.0vs Insulin IcodecNCT06340854
7 other results
- 2.7 vs 2.5 NCT05462756
- 2.0 vs -3.0 NCT01117350
- 2.2 vs 1.1 NCT00391027
- 3.5 vs 2.3 NCT00418522
- 0.4 vs -1.1 NCT00751114
- 0.5 vs 0.2 NCT00360698
- -1 vs -0.5 NCT02455076
HbA1c below 7%
- insulin detemir
- —Not posted · NCT00283751
- insulin glargine
- 48.4% vs 45.9%vs LiraglutideNCT01117350
4 other results
- 22.4% vs 8.8% NCT00360698
- 51.1% vs 39.5% NCT00384085
- 62.6% vs 47.6% NCT00418522
- 67.9% vs 41.9% NCT00751114
Fasting plasma glucose, change
- insulin detemir
- -2.1 vs -0.4vs Lira 1.8NCT00856986
2 other results
- -1.9 vs -0.1 NCT00856986
- 6.4 vs 4.9 NCT00998335
- insulin glargine
- -3.6 vs -2.1vs LiraglutideNCT01117350
4 other results
- -1.7 vs -3.3 NCT00391027
- -2.9 vs -3.0 NCT00418522
- -3.4 vs -1.1 NCT00751114
- -0.8 vs -0.8 NCT01226043
3-point MACE (% with event)
- insulin detemir
- —Not posted · NCT00283751
- insulin glargine
- —Not posted · NCT00044447
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
7 other shared endpoints and safety
Coverage. insulin detemir: 11 of 11 rows · insulin glargine: 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | insulin detemir Rows use multiple source trials | insulin glargine Rows use multiple source trials |
|---|---|---|
| BMI absolute change · kg | 0.2 vs 0.3 Insulin Detemir kg @ 26wka,b,c NCT00998335 · Phase 4 · registry result, not featured evidence · combination 1 other source trial-0.3 vs -0.58 Sitagliptin kg @ 26wk NCT00789191 · Phase 3 · registry result, not featured evidence · combination | -0.8 vs -0.7 Insulin Only kga,b,c NCT02455076 · Phase 4 · registry result, not featured evidence 2 other source trials0.7 vs 0.4 Insulin Glargine (Lantus®) kg @ 26wk NCT00391027 · Phase 4 · registry result, not featured evidence 1.22 vs 0.8 Insulin Glargine kg @ 26wk NCT00418522 · Phase 4 · registry result, not featured evidence |
| Daily Plasma Glucose Change mg/dL absolute change · mmol/L | 9.44 vs 8.49 Insulin Detemir mmol/L @ 26wk*a,d NCT00998335 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from 170 mg/dL as posted | -0.83 vs -0.11 Insulin Glargine+Metformin+Glimepiride mmol/L @ 24wk*a,d NCT00360698 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -15.01 mg/dL as posted |
| HbA1c absolute value · percentage points | 7.11% (n=234) vs 7.04% (n=239) Insulin Aspart @ 156wke,a,b,f NCT00184600 · Phase 3 · registry result, not featured evidence | 7.5% (n=49) vs 7.8% (n=57) Insulin Glargine+Metformin+Glimepiride @ 24wke,a,b,f NCT00360698 · Phase 4 · registry result, not featured evidence · combination |
| HbA1c absolute change · percentage points Change From Phase 1 Baseline to Week 36 | -0.99% (n=36) vs -1.49% (n=14) RA Insulin @ 36wka Change From Phase 1 Baseline to Week 36 NCT00467649 · Phase 4 · registry result, not featured evidence · combination | -0.99% (n=36) vs -1.49% (n=14) RA Insulin @ 36wka Change From Phase 1 Baseline to Week 36 NCT00467649 · Phase 4 · registry result, not featured evidence · combination |
| HbA1c absolute change · percentage points No placebo or comparator arm | -0.9% (n=21) @ 12wkg,a,b NCT01868542 · Phase 4 · registry result, not featured evidence show 1 more dose-0.8% (n=23) @ 12wk NCT01868542 · Phase 4 · registry result, not featured evidence | -0.641% (n=259) @ 12wka,b NCT04153981 · Phase 4 · registry result, not featured evidence |
| HbA1c Less Than 7 absolute value · percentage points | 55.9% (n=195) vs 63.3% (n=188) insulin aspart @ 32wka,b,h NCT01165684 · Phase 4 · registry result, not featured evidence | 37.7% (n=159) vs 37% (n=154) Lantus @ 40wka,b,h NCT01226043 · Phase 4 · registry result, not featured evidence |
| Weight absolute change · kg Change From Phase 1 Baseline to Week 36 | 4.51 vs 3.9 RA Insulin kg @ 36wka Change From Phase 1 Baseline to Week 36 NCT00467649 · Phase 4 · registry result, not featured evidence · combination | 4.51 vs 3.9 RA Insulin kg @ 36wka Change From Phase 1 Baseline to Week 36 NCT00467649 · Phase 4 · registry result, not featured evidence · combination |
| Dropout rate | 0%i NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 16 more results8.7%Insulin Detemir (2-4-6-8 Algorithm NCT01868542 · Phase 4 · registry result, not featured evidence 0%Insulin Detemir (3-0-3 Algorithm ) NCT01868542 · Phase 4 · registry result, not featured evidence 13.9% NCT01165684 · Phase 4 · registry result, not featured evidence 16.7% NCT00909480 · Phase 4 · registry result, not featured evidence — NCT00998335 · Phase 4 · registry result, not featured evidence · combination 0% NCT00591227 · Phase 4 · registry result, not featured evidence 6.9% NCT00455858 · Phase 4 · registry result, not featured evidence 12.3%FPG 70-90 mg/dL NCT00634842 · Phase 4 · registry result, not featured evidence 14.8%FPG 80-110 mg/dL NCT00634842 · Phase 4 · registry result, not featured evidence — NCT00467649 · Phase 4 · registry result, not featured evidence · combination 0% NCT00590226 · Phase 4 · registry result, not featured evidence · combination 19.2% NCT00184600 · Phase 3 · registry result, not featured evidence 12.6% NCT00789191 · Phase 3 · registry result, not featured evidence · combination 0%Iiraglutide NCT01232946 · Phase na · registry result, not featured evidence 18.2%Liraglutide Plus Insulin Detemir NCT01232946 · Phase na · registry result, not featured evidence · combination 15.1% NCT01837680 · Phase na · registry result, not featured evidence | 19.3%j NCT00069784 · Phase 3 show 29 more results11.3% NCT05114590 · Phase 4 · registry result, not featured evidence 28.3% NCT04153981 · Phase 4 · registry result, not featured evidence 1.3% NCT02561130 · Phase 4 · registry result, not featured evidence 8.5%Exenatide Inpatient NCT02455076 · Phase 4 · registry result, not featured evidence —Exenatide Outpatient NCT02455076 · Phase 4 · registry result, not featured evidence 2%Exenatide Plus Glargine Insulin In NCT02455076 · Phase 4 · registry result, not featured evidence · combination —Comparative Period: Insulin Glargi NCT01117350 · Phase 4 · registry result, not featured evidence —Extension Period: Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence 8.6%Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence —Crossover Phase: SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence —Observational Phase: SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence —Re-randomization Phase: SoloSTAR® NCT01226043 · Phase 4 · registry result, not featured evidence —SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence 15.2% NCT00751114 · Phase 4 · registry result, not featured evidence 12.3%0.5 Units/kg NCT00911625 · Phase 4 · registry result, not featured evidence 0%0.25 Units/kg NCT00911625 · Phase 4 · registry result, not featured evidence 23.5%Lantus/Apidra-1 NCT00384085 · Phase 4 · registry result, not featured evidence · combination 20%Lantus/Apidra-3 NCT00384085 · Phase 4 · registry result, not featured evidence · combination 33.3%Insulin Glargine at Bedtime NCT00686712 · Phase 4 · registry result, not featured evidence 44%Insulin Glargine in AM NCT00686712 · Phase 4 · registry result, not featured evidence — NCT00360698 · Phase 4 · registry result, not featured evidence · combination 18.5% NCT00391027 · Phase 4 · registry result, not featured evidence 37.9% NCT00418522 · Phase 4 · registry result, not featured evidence — NCT00467649 · Phase 4 · registry result, not featured evidence · combination 1.5% NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 —Efsitora NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 —Glargine NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 9.3%Insulin Glargine NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 4.7% NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 |
| Discontinued due to AEs | 0%i NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 16 more results—Insulin Detemir (2-4-6-8 Algorithm NCT01868542 · Phase 4 · registry result, not featured evidence —Insulin Detemir (3-0-3 Algorithm ) NCT01868542 · Phase 4 · registry result, not featured evidence 0.5% NCT01165684 · Phase 4 · registry result, not featured evidence 2.2% NCT00909480 · Phase 4 · registry result, not featured evidence — NCT00998335 · Phase 4 · registry result, not featured evidence · combination — NCT00591227 · Phase 4 · registry result, not featured evidence — NCT00455858 · Phase 4 · registry result, not featured evidence 1.6%FPG 70-90 mg/dL NCT00634842 · Phase 4 · registry result, not featured evidence 2.5%FPG 80-110 mg/dL NCT00634842 · Phase 4 · registry result, not featured evidence — NCT00467649 · Phase 4 · registry result, not featured evidence · combination — NCT00590226 · Phase 4 · registry result, not featured evidence · combination 3.8% NCT00184600 · Phase 3 · registry result, not featured evidence 1.8% NCT00789191 · Phase 3 · registry result, not featured evidence · combination —Iiraglutide NCT01232946 · Phase na · registry result, not featured evidence —Liraglutide Plus Insulin Detemir NCT01232946 · Phase na · registry result, not featured evidence · combination — NCT01837680 · Phase na · registry result, not featured evidence | 1.7%j NCT00069784 · Phase 3 show 29 more results0.8% NCT05114590 · Phase 4 · registry result, not featured evidence — NCT04153981 · Phase 4 · registry result, not featured evidence — NCT02561130 · Phase 4 · registry result, not featured evidence 6.4%Exenatide Inpatient NCT02455076 · Phase 4 · registry result, not featured evidence —Exenatide Outpatient NCT02455076 · Phase 4 · registry result, not featured evidence 0%Exenatide Plus Glargine Insulin In NCT02455076 · Phase 4 · registry result, not featured evidence · combination —Comparative Period: Insulin Glargi NCT01117350 · Phase 4 · registry result, not featured evidence —Extension Period: Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence 1.2%Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence —Crossover Phase: SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence —Observational Phase: SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence —Re-randomization Phase: SoloSTAR® NCT01226043 · Phase 4 · registry result, not featured evidence —SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence 0.8% NCT00751114 · Phase 4 · registry result, not featured evidence —0.5 Units/kg NCT00911625 · Phase 4 · registry result, not featured evidence —0.25 Units/kg NCT00911625 · Phase 4 · registry result, not featured evidence 2.6%Lantus/Apidra-1 NCT00384085 · Phase 4 · registry result, not featured evidence · combination 2.6%Lantus/Apidra-3 NCT00384085 · Phase 4 · registry result, not featured evidence · combination 3.3%Insulin Glargine at Bedtime NCT00686712 · Phase 4 · registry result, not featured evidence 4%Insulin Glargine in AM NCT00686712 · Phase 4 · registry result, not featured evidence — NCT00360698 · Phase 4 · registry result, not featured evidence · combination 5.9% NCT00391027 · Phase 4 · registry result, not featured evidence 3.2% NCT00418522 · Phase 4 · registry result, not featured evidence — NCT00467649 · Phase 4 · registry result, not featured evidence · combination — NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 —Efsitora NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 —Glargine NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 —Insulin Glargine NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 0.8% NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 |
| Serious AEs | 10.4%i NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 16 more results4.3%Insulin Detemir (2-4-6-8 Algorithm NCT01868542 · Phase 4 · registry result, not featured evidence 0%Insulin Detemir (3-0-3 Algorithm ) NCT01868542 · Phase 4 · registry result, not featured evidence 9.1% NCT01165684 · Phase 4 · registry result, not featured evidence 3.1% NCT00909480 · Phase 4 · registry result, not featured evidence 0% NCT00998335 · Phase 4 · registry result, not featured evidence · combination 0% NCT00591227 · Phase 4 · registry result, not featured evidence 5.7% NCT00455858 · Phase 4 · registry result, not featured evidence 4.1%FPG 70-90 mg/dL NCT00634842 · Phase 4 · registry result, not featured evidence 3.3%FPG 80-110 mg/dL NCT00634842 · Phase 4 · registry result, not featured evidence 0% NCT00467649 · Phase 4 · registry result, not featured evidence · combination 22.4% NCT00590226 · Phase 4 · registry result, not featured evidence · combination 33.3% NCT00184600 · Phase 3 · registry result, not featured evidence 1.9% NCT00789191 · Phase 3 · registry result, not featured evidence · combination 0%Iiraglutide NCT01232946 · Phase na · registry result, not featured evidence 0%Liraglutide Plus Insulin Detemir NCT01232946 · Phase na · registry result, not featured evidence · combination 0% NCT01837680 · Phase na · registry result, not featured evidence | 4.9%j NCT00069784 · Phase 3 show 29 more results0.8% NCT05114590 · Phase 4 · registry result, not featured evidence 0.4% NCT04153981 · Phase 4 · registry result, not featured evidence 3.9% NCT02561130 · Phase 4 · registry result, not featured evidence 14.9%Exenatide Inpatient NCT02455076 · Phase 4 · registry result, not featured evidence 22.9%Exenatide Outpatient NCT02455076 · Phase 4 · registry result, not featured evidence 23.5%Exenatide Plus Glargine Insulin In NCT02455076 · Phase 4 · registry result, not featured evidence · combination 2.3%Comparative Period: Insulin Glargi NCT01117350 · Phase 4 · registry result, not featured evidence 3.1%Extension Period: Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence —Insulin Glargine NCT01117350 · Phase 4 · registry result, not featured evidence 1%Crossover Phase: SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence 10.1%Observational Phase: SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence 0.6%Re-randomization Phase: SoloSTAR® NCT01226043 · Phase 4 · registry result, not featured evidence —SoloSTAR® Pen NCT01226043 · Phase 4 · registry result, not featured evidence 6.3% NCT00751114 · Phase 4 · registry result, not featured evidence 0%0.5 Units/kg NCT00911625 · Phase 4 · registry result, not featured evidence 0%0.25 Units/kg NCT00911625 · Phase 4 · registry result, not featured evidence 11.9%Lantus/Apidra-1 NCT00384085 · Phase 4 · registry result, not featured evidence · combination 11.3%Lantus/Apidra-3 NCT00384085 · Phase 4 · registry result, not featured evidence · combination 0%Insulin Glargine at Bedtime NCT00686712 · Phase 4 · registry result, not featured evidence 4%Insulin Glargine in AM NCT00686712 · Phase 4 · registry result, not featured evidence 2% NCT00360698 · Phase 4 · registry result, not featured evidence · combination 5.9% NCT00391027 · Phase 4 · registry result, not featured evidence — NCT00418522 · Phase 4 · registry result, not featured evidence 0% NCT00467649 · Phase 4 · registry result, not featured evidence · combination 5.8% NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 6.5%Efsitora NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 5.3%Glargine NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 —Insulin Glargine NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 6.8% NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 |
| Most frequent reported AEs | i nasopharyngitis 20.2% nausea 18.4% diarrhoea 17.8% NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 13 more resultsnasopharyngitis 13% headache 8.7% upper respiratory tract infection 4.3% NCT01868542 · Phase 4 · registry result, not featured evidence nasopharyngitis 13% rash 8.7% upper respiratory tract infection 8.7% NCT01868542 · Phase 4 · registry result, not featured evidence nasopharyngitis 8.1% headache 5.1% influenza 5.1% NCT01165684 · Phase 4 · registry result, not featured evidence nasopharyngitis 10.6% upper respiratory tract infection 8% headache 7.5% NCT00909480 · Phase 4 · registry result, not featured evidence nasopharyngitis 11.5% upper respiratory tract infection 5.7% NCT00455858 · Phase 4 · registry result, not featured evidence back pain 5.8% headache 5% upper respiratory tract infection 5% NCT00634842 · Phase 4 · registry result, not featured evidence pain in extremity 3.3% urinary tract infection 3.3% anxiety 2.5% NCT00634842 · Phase 4 · registry result, not featured evidence nausea 11.1% diarrhoea 5.6% hypertension 5.6% NCT00467649 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 46.2% diarrhoea 25.6% infection 21.4% NCT00184600 · Phase 3 · registry result, not featured evidence headache 14.5% nasopharyngitis 13.2% back pain 10.5% NCT00789191 · Phase 3 · registry result, not featured evidence · combination gastrointestinal intolerance 0% NCT01232946 · Phase na · registry result, not featured evidence gastrointestinal intolerance 18.2% NCT01232946 · Phase na · registry result, not featured evidence · combination biochemical event of hypoglycemia 50.9% symptomatic hypoglycemia 30.2% symptomatic nocturnal event 15.1% NCT01837680 · Phase na · registry result, not featured evidence | j hypoglycaemia 5.7% upper respiratory tract infection 5.7% NCT05114590 · Phase 4 · registry result, not featured evidence show 22 more resultsanaemia 1.9% cough 0.4% hyperglycaemia 0.4% NCT04153981 · Phase 4 · registry result, not featured evidence genitourinary infection 5.2% abdominal pain 3.9% injury 3.9% NCT02561130 · Phase 4 · registry result, not featured evidence nausea 9.8% vomiting 5.9% NCT02455076 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 7.9% headache 5% diarrhoea 3.7% NCT01117350 · Phase 4 · registry result, not featured evidence nasopharyngitis 7.5% diarrhoea 3.1% headache 1.3% NCT01117350 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 1.8% nasopharyngitis 1.3% sinusitis 1% NCT01226043 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 8.8% sinusitis 7.5% oedema peripheral 5% NCT01226043 · Phase 4 · registry result, not featured evidence nasopharyngitis 3.6% upper respiratory tract infection 2.4% sinusitis 1.2% NCT01226043 · Phase 4 · registry result, not featured evidence headache 6.3% influenza 3.4% nasopharyngitis 3.4% NCT00751114 · Phase 4 · registry result, not featured evidence any infections and infestations 42.3% any musculoskeletal and connective tissue disorders 22.7% any gastrointestinal disorders 16.5% NCT00384085 · Phase 4 · registry result, not featured evidence · combination any infections and infestations 34% any musculoskeletal and connective tissue disorders 23.2% any nervous system disorders 20.1% NCT00384085 · Phase 4 · registry result, not featured evidence · combination symptomatic hypoglycemia 76.7% asymptomatic retinal hemorrhage 3.3% urinary tract infection 0% NCT00686712 · Phase 4 · registry result, not featured evidence symptomatic hypoglycemia 96% asymptomatic retinal hemorrhage 0% urinary tract infection 0% NCT00686712 · Phase 4 · registry result, not featured evidence hypoglycaemia 70.4% nasopharyngitis 13.3% cough 6.7% NCT00391027 · Phase 4 · registry result, not featured evidence hypoglycaemia 67.9% tremor 31.6% dizziness 18.9% NCT00418522 · Phase 4 · registry result, not featured evidence nausea 11.1% diarrhoea 5.6% hypertension 5.6% NCT00467649 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 7.8% diabetic retinopathy 7.3% diarrhoea 1.9% NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 influenza 7.3% covid-19 5.3% hypertension 5.3% NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 drug titration error 9.8% urinary tract infection 6.3% influenza 5.8% NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 nasopharyngitis 6.3% influenza 3.8% NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cThe assessment timepoint is not available for both results.
- dAssessment timepoints differ: 24 weeks versus 26 weeks.
- eTrial phases differ: Phase 4 versus Phase 3.
- fAssessment timepoints differ: 24 weeks versus 156 weeks.
- gThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- hAssessment timepoints differ: 40 weeks versus 32 weeks.
- iPopulation comparability has not been reviewed for 16 of these studies.
- jPopulation comparability has not been reviewed for 25 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
insulin detemir
show 3 more results
show 5 more results
show 2 more results
+ 26 further endpoints in the CSV export.
insulin glargine
show 1 more result
+ 56 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin detemir's landscape · insulin glargine's landscape